Cancer Research UK, University of Southampton and Touchlight Genetics partner to develop head and neck cancer vaccine
Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Touchlight to develop biobatteries with potential to address limitations of portable power supply
Supported by the Office of Naval Research Global (ONR Global) and the UK's Defense Science and Technology Laboratory (DSTL), Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, is working together with the Minteer Lab, University of Utah, to develop a DNA-enabled biobattery that could revolutionise portable and off-grid power supply.
Touchlight’s Chairman to help lead UK Covid-19 vaccine effort
Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this role, Clive will be responsible for building the UK’s vaccine response to Covid-19.